Settings
UTHR [NASD]
United Therapeutics Corporation
Index- P/E41.63 EPS (ttm)3.39 Insider Own0.10% Shs Outstand47.51M Perf Week-2.87%
Market Cap6.71B Forward P/E14.29 EPS next Y9.88 Insider Trans-95.69% Shs Float46.91M Perf Month7.90%
Income193.80M PEG1.51 EPS next Q2.09 Inst Own- Short Float8.91% Perf Quarter8.06%
Sales1.23B P/S5.45 EPS this Y-42.60% Inst Trans0.06% Short Ratio7.00 Perf Half Y55.19%
Book/sh25.72 P/B5.49 EPS next Y43.68% ROA9.40% Target Price129.53 Perf Year32.74%
Cash/sh16.16 P/C8.73 EPS next 5Y27.63% ROE15.20% 52W Range84.63 - 149.02 Perf YTD8.99%
Dividend- P/FCF21.59 EPS past 5Y38.20% ROI11.80% 52W High-5.29% Beta1.40
Dividend %- Quick Ratio1.30 Sales past 5Y31.70% Gross Margin87.90% 52W Low66.76% ATR4.31
Employees706 Current Ratio1.40 Sales Q/Q9.20% Oper. Margin26.90% RSI (14)55.85 Volatility2.77% 3.11%
OptionableYes Debt/Eq0.24 EPS Q/Q-145.30% Profit Margin15.70% Rel Volume0.95 Prev Close142.57
ShortableYes LT Debt/Eq0.00 EarningsFeb 23 BMO Payout0.00% Avg Volume597.19K Price141.13
Recom2.60 SMA203.02% SMA506.01% SMA20025.08% Volume567,535 Change-1.01%
Nov-03-14Downgrade Argus Buy → Hold
Oct-15-14Upgrade Standpoint Research Hold → Buy $144
Aug-29-14Reiterated Standpoint Research Buy $118 → $140
Jul-30-14Reiterated H.C. Wainwright Buy $120 → $150
Apr-07-14Upgrade Standpoint Research Hold → Buy $118
Feb-26-14Reiterated RBC Capital Mkts Sector Perform $80 → $90
Feb-26-14Reiterated Ladenburg Thalmann Buy $138 → $135
Dec-31-13Reiterated Argus Buy $120 → $130
Dec-23-13Upgrade Ladenburg Thalmann Neutral → Buy $138
Dec-02-13Reiterated Argus Buy $85 → $110
Aug-05-13Reiterated Argus Buy $75 → $85
Jul-30-13Downgrade Standpoint Research Buy → Hold
Jun-20-13Upgrade Standpoint Research Hold → Buy
May-15-13Downgrade Standpoint Research Buy → Hold
Mar-25-13Reiterated Ladenburg Thalmann Buy $69 → $63
Feb-27-13Reiterated RBC Capital Mkts Sector Perform $45 → $50
Aug-03-12Downgrade Standpoint Research Buy → Hold
Apr-27-12Downgrade Canaccord Genuity Buy → Hold
Mar-26-12Initiated Canaccord Genuity Buy $56
Mar-12-12Initiated Standpoint Research Buy $65
Jan-16-15 06:44PM  Ulta Among IBD 50 Stocks Setting Up In Shaky Market at Investor's Business Daily
02:20PM  Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog Zacks
Jan-15-15 05:33PM  NetEase, Other Leading Stocks Break Out To New Highs at Investor's Business Daily
12:50PM  Biotech Stock United Therapeutics Tests New Buy Point at Investor's Business Daily
Jan-06-15 09:50PM  United Therapeutics Corporation To Present At 33rd Annual J.P. Morgan Healthcare Conference PR Newswire
01:03PM  UPDATE: Barclays Initiates Coverage On United Therapeutics Benzinga
Jan-05-15 07:14PM  UPDATE: BTIG Initiates Coverage On United Therapeutics Benzinga
Dec-31-14 06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
06:00AM  United Therapeutics Announces Signing Of Agreement For New Remodulin Delivery System PR Newswire
Dec-24-14 11:48AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
11:26AM  United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin PR Newswire
Dec-19-14 05:20PM  United Therapeutics Lung Drug Keeps Going And Going at Investor's Business Daily
Dec-17-14 06:02AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princ EDGAR Online
06:00AM  United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change PR Newswire
Dec-11-14 11:48AM  Can United Therapeutics find a remedy for recent resistance? at Investor's Business Daily
Dec-08-14 01:25PM  Stocks Fall To Session Lows: GoPro Gives Up More Ground at Investor's Business Daily
Nov-26-14 05:40PM  Stock Market Today: Top Biotech Is Near Buy Point at Investor's Business Daily
Nov-13-14 06:44AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
06:00AM  Professor Katherine J. Klein Joins The United Therapeutics Corporation Board Of Directors PR Newswire
Nov-03-14 08:45AM  United Therapeutics downgraded by Argus Briefing.com
Nov-01-14 01:04PM  UNITED THERAPEUTICS CORP Financials EDGAR Online Financials
Oct-30-14 08:08PM  10-Q for United Therapeutics Corp. Company Spotlight
07:59PM  Apple CEO publicly acknowledges that he's gay AP
Oct-29-14 11:50AM  United Therapeutics Falls on Q3 Loss, Revenues Miss Zacks
Oct-28-14 07:07AM  Q3 2014 United Therapeutics Corp Earnings Release - Before Market Open CCBN
06:27AM  United Therapeutics reports 3Q loss AP
06:05AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:04AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports Third Quarter 2014 Financial Results PR Newswire
Oct-22-14 05:01PM  Biotechs Show Fed Chief's Not Much Of A Stock Analyst at Investor's Business Daily
Oct-21-14 06:00AM  United Therapeutics Corporation To Announce Third Quarter 2014 Financial Results Before Market Open On Tuesday, October 28, 2014 PR Newswire
Oct-14-14 05:05PM  Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 Zacks
10:27AM  J&J Beats Q3 Earnings on Strong Drug Sales, Ups View Zacks
Sep-26-14 03:07PM  Biotech's future: The Government is key Yahoo Finance
Sep-25-14 12:34PM  Artificial intelligence doppelgangers and life in outer space closer than you think Yahoo Finance
08:38AM  Highest-paid female CEO used to be a man Yahoo Finance
Sep-24-14 09:36AM  Can the Uptrend Continue for United Therapeutics (UTHR)? Zacks
Sep-23-14 05:21PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
08:10AM  Moving Average Crossover Alert: United Therapeutics (UTHR) Zacks
Sep-22-14 05:11PM  Today's Market Thorns, Roses and All Time Highs... Yahoo Finance Blogs
Sep-17-14 07:30AM  Axsome Therapeutics Announces Appointments to Its Board of Directors GlobeNewswire
Sep-16-14 03:00AM  Pluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market GlobeNewswire
Sep-15-14 05:32PM  Today's Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
11:19AM  Hedge fund offers $1 million to cure...aging? at CNBC
Sep-10-14 04:20PM  Spectrum Pharmaceuticals to Advance Neutropenia Drug Zacks
Sep-09-14 03:50PM  Pluristem & United Therapeutics Progress with Phase I Study Zacks
Sep-03-14 04:20PM  Arena Pharmaceuticals' APD811 Gets Orphan Drug Status Zacks
09:10AM  Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Zacks
Sep-02-14 05:25PM  United Therapeutics Soars on Remodulin Patent Case Win Zacks
07:58AM  United Therapeutics (UTHR) Shares March Higher, Can It Continue? Zacks
Aug-29-14 04:21PM  United Therapeutics Legal Victory Sends Stock Flying at Investor's Business Daily +28.51%
02:21PM  United Therapeutics Up 27% as Patent Win 'Close to a Best Case Scenario' at Barrons.com
02:02PM  United Therapeutics rises on drug-patent ruling AP
12:49PM  District Court Decision Received In Remodulin Patent Case PR Newswire
Aug-26-14 07:50AM  Catalyst Pharmaceutical Partners (CPRX) Worth Watching: Stock Up 10.3% Zacks
Aug-25-14 11:05AM  Roche Buying InterMune for $8.3 Billion; Investors Want More Pharma Deals StockTwits
Aug-22-14 04:40PM  OncoGenex's Custirsen Passes First Interim Futility Analysis Zacks
08:25AM  Flamel Technologies SA (FLML) in Focus: Stock Rises 8% Zacks
Aug-21-14 08:56AM  Gilead (GILD) Hits 52-Week High Thanks to Sovaldi Zacks
Aug-20-14 05:21PM  Alcobra Starts Patient Enrollment for Mid-Stage Study on MDX Zacks
08:40AM  Salix Pharmaceuticals (SLXP) Jumps: Stock Moves 15.5% Higher Zacks
06:51AM  Can United Therapeutics (UTHR) Keep the Earnings Streak Alive This Quarter? Zacks
Aug-14-14 02:30PM  Rigel's R348 Fails in Phase II Study, Shares Down 13.6% Zacks
Jul-31-14 12:20PM  United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat Zacks
Jul-30-14 10:56AM  Perilous Reversal Watch: United Therapeutics (UTHR) at TheStreet -5.01%
07:08AM  United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session Zacks
Jul-29-14 07:07AM  Q2 2014 United Therapeutics Earnings Release - Before Market Open CCBN +8.10%
06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:03AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports Second Quarter 2014 Financial Results PR Newswire
Jul-22-14 06:00AM  United Therapeutics Corporation To Announce Second Quarter 2014 Financial Results Before Market Open On Tuesday, July 29, 2014 PR Newswire
Jul-10-14 03:43PM  Supernus Up on Non-Dilutive Royalty Deal Zacks
Jul-09-14 05:00PM  Pluristem Initiates Trial in South Korea Zacks
Jul-08-14 07:30AM  Supernus to Receive $30 Million in Non-Dilutive Royalty Deal GlobeNewswire
05:47AM  United Therapeutics draws bulls optionMONSTER
Jun-27-14 09:14AM  Today's Top Biotech Stocks: Bristol-Myers Squibb, United Therapeutics and Vertex Pharmaceuticals at Motley Fool
06:02AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc EDGAR Online
06:00AM  United Therapeutics Announces Additional $500 Million Share Repurchase Program PR Newswire
Jun-19-14 01:18PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into United Therapeutics Corporation Regarding Possible Breaches of Fiduciary Duty Business Wire
Jun-16-14 09:49AM  United Therapeutics (UTHR) Marked As A Dead Cat Bounce Stock at TheStreet
07:26AM  Weakness Seen in United Therapeutics (UTHR): Stock Tumbles 8.0% Zacks
Jun-13-14 04:46PM  Can Pig Lungs Keep Growth Flying for United Therapeutics Shareholders? at Motley Fool -7.97%
Jun-09-14 02:34PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into United Therapeutics Corporation Regarding Possible Breaches of Fiduciary Duty PR Newswire
May-21-14 05:34PM  [video] Momentum trades alive: ARCB, UTHR at CNBC
May-20-14 05:00PM  Supernus Receives $2 Million Milestone for United Therapeutics' Launch of Orenitram(TM) GlobeNewswire
11:19AM  Why I'm Long Supernus, A Small Specialty Pharma Company at Seeking Alpha
May-13-14 11:12AM  3 picks for bent but not broken biotech Breakout
May-11-14 05:45AM  Industry Ranks May 2014 at Seeking Alpha
May-08-14 12:16PM  Insider Trading Alert - K, EQR And UTHR Traded By Insiders at TheStreet
May-06-14 06:07AM  Pig organ transplants to humans move a step closer at Financial Times
06:00AM  Synthetic Genomics Inc. Signs Collaborative Research and Development Agreement with Lung Biotechnology Inc., a Subsidiary of United Therapeutics Corporation, to Develop Humanized Pig Organs to Revolutionize Transplantation Field PR Newswire
06:00AM  Genome scientist Craig Venter in deal to make humanized pig organs Reuters
May-05-14 06:32PM  3 Biotech Stocks Making Big Moves Last Week at Motley Fool
May-01-14 12:10PM  United Therapeutics Gains on Q1 Earnings Zacks
Apr-29-14 06:00PM  United Therapeutics Management Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha +6.13%
07:07AM  Q1 2014 United Therapeutics Earnings Release - Before Market Open CCBN
06:04AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:04AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports First Quarter 2014 Financial Results PR Newswire
Apr-22-14 06:00AM  United Therapeutics Corporation To Announce First Quarter 2014 Financial Results Before Market Open On Tuesday, April 29, 2014 PR Newswire
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE AChairman & Co-CEOJan 29Option Exercise32.379,662312,7855,687Jan 30 05:43 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 29Sale143.299,6621,384,502140Jan 30 05:43 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 28Option Exercise63.222,211139,7792,351Jan 28 05:05 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 28Sale145.492,211321,684140Jan 28 05:05 PM
JEFFS ROGERPresident & Co-CEOJan 27Option Exercise50.0910,000500,90011,234Jan 28 04:28 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 27Option Exercise50.094,000200,3605,153Jan 28 04:32 PM
JEFFS ROGERPresident & Co-CEOJan 27Sale147.1910,0001,471,9001,234Jan 28 04:28 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 27Sale147.194,000588,7601,153Jan 28 04:32 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 26Option Exercise52.652,592136,4692,732Jan 27 07:27 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 26Sale145.892,592378,136140Jan 27 07:27 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 22Option Exercise32.379,662312,7855,687Jan 22 09:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 22Sale146.649,6621,416,862140Jan 22 09:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 21Option Exercise63.222,211139,7792,351Jan 22 09:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 21Sale147.262,211325,602140Jan 22 09:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 20Option Exercise52.652,592136,4692,732Jan 20 05:52 PM
JEFFS ROGERPresident & Co-CEOJan 20Option Exercise50.0910,000500,90011,234Jan 22 08:31 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 20Option Exercise50.094,000200,3605,153Jan 22 08:37 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 20Sale145.062,592375,993140Jan 20 05:52 PM
JEFFS ROGERPresident & Co-CEOJan 20Sale146.4810,0001,464,8001,234Jan 22 08:31 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 20Sale146.484,000585,9201,153Jan 22 08:37 PM
Ferrari John MaximCFOJan 15Option Exercise51.3722,5001,155,82522,907Jan 15 09:21 PM
MAHON PAUL AEVP & General CounselJan 15Option Exercise33.146,000198,84040,832Jan 15 09:31 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 15Option Exercise32.379,662312,7855,687Jan 15 09:44 PM
Ferrari John MaximCFOJan 15Sale137.8422,5003,101,400407Jan 15 09:21 PM
MAHON PAUL AEVP & General CounselJan 15Sale137.846,000827,04034,832Jan 15 09:31 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 15Sale137.519,6621,328,670140Jan 15 09:44 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 14Option Exercise63.222,211139,7792,351Jan 14 07:15 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 14Sale135.182,211298,887140Jan 14 07:15 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 13Option Exercise50.093,000150,2704,153Jan 14 07:20 PM
JEFFS ROGERPresident & Co-CEOJan 13Option Exercise50.0910,000500,90011,234Jan 14 07:27 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 13Sale134.713,000404,1301,153Jan 14 07:20 PM
JEFFS ROGERPresident & Co-CEOJan 13Sale134.7110,0001,347,1001,234Jan 14 07:27 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 12Option Exercise52.652,592136,4692,732Jan 13 04:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 12Sale132.002,592342,148140Jan 13 04:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 08Option Exercise32.379,662312,7855,687Jan 08 08:00 PM
PATUSKY CHRISTOPHERDirectorJan 08Option Exercise41.145,000205,7005,000Jan 12 08:35 AM
ROTHBLATT MARTINE AChairman & Co-CEOJan 08Sale128.319,6621,239,695140Jan 08 08:00 PM
PATUSKY CHRISTOPHERDirectorJan 08Sale128.135,000640,6500Jan 12 08:35 AM
ROTHBLATT MARTINE AChairman & Co-CEOJan 07Option Exercise63.222,211139,7792,351Jan 07 08:48 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 07Sale126.042,211278,683140Jan 07 08:48 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 06Option Exercise49.663,000148,9753,653Jan 07 08:23 PM
JEFFS ROGERPresident & Co-CEOJan 06Option Exercise50.097,500375,6758,734Jan 07 08:31 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 06Sale124.933,000374,7901,153Jan 07 08:23 PM
JEFFS ROGERPresident & Co-CEOJan 06Sale124.937,500936,9751,234Jan 07 08:31 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 05Option Exercise52.652,592136,4692,732Jan 06 08:19 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 05Sale126.882,592328,862140Jan 06 08:19 PM
CAUSEY CHRISTOPHERDirectorJan 02Option Exercise41.143,000123,4203,733Jan 02 09:30 PM
DWEK RAYMONDDirectorJan 02Option Exercise31.173,00093,5103,000Jan 02 09:34 PM
MAHON PAUL AEVP & General CounselJan 02Option Exercise33.146,000198,84040,832Jan 02 09:38 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 02Option Exercise32.379,662312,7855,687Jan 02 09:26 PM
CAUSEY CHRISTOPHERDirectorJan 02Sale129.253,000387,751733Jan 02 09:30 PM
DWEK RAYMONDDirectorJan 02Sale129.173,000387,5240Jan 02 09:34 PM
MAHON PAUL AEVP & General CounselJan 02Sale127.736,000766,38034,832Jan 02 09:38 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 02Sale126.539,6621,222,571140Jan 02 09:26 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 31Option Exercise63.222,211139,7792,351Jan 02 08:36 AM
ROTHBLATT MARTINE AChairman & Co-CEODec 31Sale131.352,211290,424140Jan 02 08:36 AM
JEFFS ROGERPresident & Co-CEODec 30Option Exercise50.0910,000500,90011,234Jan 02 08:34 AM
JEFFS ROGERPresident & Co-CEODec 30Sale130.8010,0001,308,0001,234Jan 02 08:34 AM
ROTHBLATT MARTINE AChairman & Co-CEODec 29Option Exercise52.652,592136,4692,732Dec 29 08:08 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 29Sale131.752,592341,507140Dec 29 08:08 PM
ROTHBLATT MARTINE ACEODec 26Option Exercise32.379,662312,7855,687Dec 29 07:19 AM
ROTHBLATT MARTINE ACEODec 26Sale131.859,6621,273,935140Dec 29 07:19 AM
ROTHBLATT MARTINE ACEODec 24Option Exercise63.222,211139,7792,351Dec 24 06:47 PM
ROTHBLATT MARTINE ACEODec 24Sale130.352,211288,202140Dec 24 06:47 PM
JEFFS ROGERPresident & COODec 23Option Exercise50.0910,000500,90011,234Dec 23 08:06 PM
JEFFS ROGERPresident & COODec 23Sale127.8210,0001,278,2001,234Dec 23 08:06 PM
ROTHBLATT MARTINE ACEODec 22Option Exercise52.652,592136,4692,732Dec 23 05:00 PM
ROTHBLATT MARTINE ACEODec 22Sale133.452,592345,904140Dec 23 05:00 PM
CAUSEY CHRISTOPHERDirectorDec 19Option Exercise41.141,50061,7102,233Dec 19 05:38 PM
CAUSEY CHRISTOPHERDirectorDec 19Sale131.471,500197,205733Dec 19 05:38 PM
ROTHBLATT MARTINE ACEODec 18Option Exercise32.379,662312,7855,687Dec 19 05:21 PM
MAHON PAUL AEVP & General CounselDec 18Option Exercise32.0810,750344,90340,832Dec 19 05:35 PM
Ferrari John MaximCFODec 18Option Exercise51.3710,000513,70010,407Dec 19 05:42 PM
ROTHBLATT MARTINE ACEODec 18Sale129.069,6621,246,931140Dec 19 05:21 PM
MAHON PAUL AEVP & General CounselDec 18Sale130.0310,7501,397,82834,832Dec 19 05:35 PM
Ferrari John MaximCFODec 18Sale131.1110,0001,311,100407Dec 19 05:42 PM
ROTHBLATT MARTINE ACEODec 17Option Exercise63.222,211139,7792,351Dec 18 04:01 PM
ROTHBLATT MARTINE ACEODec 17Sale126.042,211278,668140Dec 18 04:01 PM
ROTHBLATT MARTINE ACEODec 15Option Exercise52.652,592136,4692,732Dec 16 05:52 PM
ROTHBLATT MARTINE ACEODec 15Sale129.752,592336,314140Dec 16 05:52 PM
ROTHBLATT MARTINE ACEODec 11Option Exercise32.379,662312,7855,687Dec 15 07:26 AM
ROTHBLATT MARTINE ACEODec 11Sale130.989,6621,265,540140Dec 15 07:26 AM
ROTHBLATT MARTINE ACEODec 10Option Exercise63.222,211139,7792,351Dec 11 08:15 AM
ROTHBLATT MARTINE ACEODec 10Sale132.772,211293,544140Dec 11 08:15 AM
JEFFS ROGERPresident & COODec 09Option Exercise50.0910,000500,90011,234Dec 09 07:21 PM
JEFFS ROGERPresident & COODec 09Sale134.8010,0001,348,0001,234Dec 09 07:21 PM
ROTHBLATT MARTINE ACEODec 08Option Exercise52.652,592136,4692,732Dec 08 08:08 PM
ROTHBLATT MARTINE ACEODec 08Sale132.342,592343,013140Dec 08 08:08 PM
ROTHBLATT MARTINE ACEODec 04Option Exercise32.379,662312,7855,687Dec 04 07:30 PM
CAUSEY CHRISTOPHERDirectorDec 04Option Exercise41.141,50061,7102,233Dec 04 07:35 PM
DWEK RAYMONDDirectorDec 04Option Exercise31.173,00093,5103,000Dec 04 07:39 PM
MAHON PAUL AEVP & General CounselDec 04Option Exercise32.0511,000352,59040,832Dec 04 07:47 PM
PATUSKY CHRISTOPHERDirectorDec 04Option Exercise41.145,000205,7005,000Dec 04 07:50 PM
Ferrari John MaximCFODec 04Option Exercise51.3710,000513,70010,407Dec 04 07:53 PM
ROTHBLATT MARTINE ACEODec 04Sale131.019,6621,265,778140Dec 04 07:30 PM
CAUSEY CHRISTOPHERDirectorDec 04Sale131.471,500197,206733Dec 04 07:35 PM
DWEK RAYMONDDirectorDec 04Sale131.583,000394,7510Dec 04 07:39 PM
MAHON PAUL AEVP & General CounselDec 04Sale129.9211,0001,429,12334,832Dec 04 07:47 PM
PATUSKY CHRISTOPHERDirectorDec 04Sale129.055,000645,2500Dec 04 07:50 PM
Ferrari John MaximCFODec 04Sale129.0510,0001,290,500407Dec 04 07:53 PM